Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wallin, Jeffrey J ^a   Bendell, Johanna C ^b   Funke, Roel ^a   Sznol, Mario ^c   Korski, Konstanty ^d   Jones, Suzanne ^b   Hernandez, Genevive ^a   Mier, James ^e   He, Xian ^a   Hodi, F Stephen ^f   Denker, Mitchell ^a   Leveque, Vincent ^a   Cañamero, Marta ^d   Babitski, Galina ^d   Koeppen, Hartmut ^a   Ziai, James ^a   Sharma, Neeraj ^a   Gaire, Fabien ^d   Chen, Daniel S ^a   Waterkamp, Daniel ^a   Hegde, Priti S ^a   McDermott, David F ^e   more..

^a GENENTECH INC   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c YALE CANCER CENTER   (United States)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; PROGRAMMED DEATH 1 LIGAND 1; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTIBODY; ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; CHEMORECEPTION; DRUG; GENETIC MARKER; TUMOR;

ADULT; ANTIANGIOGENIC THERAPY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR BIOPSY; TUMOR IMMUNITY; TUMOR VOLUME; AGED; ANTAGONISTS AND INHIBITORS; CELL MOTION; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; IMMUNOLOGY; KIDNEY; KIDNEY TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RENAL CELL CARCINOMA; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; BEVACIZUMAB; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; DRUG SYNERGISM; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84984870923     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12624     Document Type: Article

References (28)

1. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
2. Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691-10696 (2004).
3. Akbari, O. et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 3, 81-91 (2010).
4. Matsumoto, K. et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem. Biophys. Res. Commun. 365, 170-175 (2008).
5. McDermott, D. F. et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833-842 (2016).
6. Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858 (1989).
7. Voron, T. et al. Control of the immune response by pro-angiogenic factors. Front. Oncol. 4, 70 (2014).
8. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007).
9. Hodi, F. S. et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632-642 (2014).
10. Bendell, J. P. et al. in ASCO Gastrointestinal Cancers Symposium (San Francisco, CA) http://meetinglibrary.asco.org/content/140258-158 (2015).
11. Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
12. Brauer, M. J. et al. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin. Cancer Res. 19, 3681-3692 (2013).
13. Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607-615 (2014).
14. Gasparini, G., Longo, R., Toi, M. & Ferrara, N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2, 562-577 (2005).
15. Lamagna, C., Aurrand-Lions, M. & Imhof, B. A. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 80, 705-713 (2006).
16. Ghosh, S., Paul, A. & Sen, E. Tumor necrosis factor alpha-induced hypoxiainducible factor 1alpha-beta-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling. Mol. Cell. Biol. 33, 2718-2731 (2013).
17. Florcken, A. et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum. Vaccin. Immunother. 9, 1217-1227 (2013).
18. Kessler, J. H. et al. Efficient identification of novel HLA-A(∗)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193, 73-88 (2001).
19. Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012).
20. Zhao, X. et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J. Immunol. 188, 1782-1788 (2012).
21. Szukiewicz, D. et al. Fractalkine (CX3CL1) and its receptor CX3CR1 may contribute to increased angiogenesis in diabetic placenta. Mediators Inflamm. 2013, 437576 (2013).
22. Umehara, H. et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24, 34-40 (2004).
23. Nishimura, M. et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J. Immunol. 168, 6173-6180 (2002).
24. Klinger, M. et al. Multiplex identification of antigen-specific T cell receptors using a combination of immune assays and immune receptor sequencing. PLoS ONE 10, e0141561 (2015).
25. Manning, E. A. et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13, 3951-3959 (2007).
26. Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171-6180 (2010).
27. Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).
28. Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099-4107 (2009).